Olesja Popow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olesja Popow has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Kevin M. Haigis
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
53 shared publications - Joao A. Paulo
Department of Cell Biology, Harvard Medical School, Boston, MA, USA
20 shared publications Alejandro Rojas-Fernandez
19 shared publications- Ian Paterson Newton
University of Dundee
19 shared publications - Inke Näthke
School of Life Sciences, University of Dundee, Dundee, United Kingdom
19 shared publications Jens Januschke
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
Extended data related to Figure 6.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
Extended data related to Figure 6.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KPC cell lines utilize direct KRAS-PI3K–mediated signaling. A, Immunoblot of KRAS mutants expressed in hTERT-HPNE E6/E7 cell lines for 48 hours with doxycycline-induced KRAS expression. The image is representative of three independent experiments. B, Immunoblot of NIH “RASless” MEFs expressing BRAFV600E and KRASWT/G12D/R. The image is representative of three independent experiments. C, Immunoblot analysis from murine KPC cell lines after inhibition using the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Blots are representative of two independent experiments. D, Immunoblot analysis of human KRASG12D PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of three independent experiments. E, Immunoblots with human KRASG12D PDX VMP PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of two independent experiments. F, Box-and-whisker plot with quantification of pAKTT308 in murine PDAC from C and human PDAC from D and E. P values were calculated using a Student t test comparing MRTX1133-treated cells with vehicle-treated cells. ***, P < 0.0002; ns, nonsignificant, P > 0.05. Error bars, mean ± SEM. Statistical tests were run using R 4.2.2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KPC cell lines utilize direct KRAS-PI3K–mediated signaling. A, Immunoblot of KRAS mutants expressed in hTERT-HPNE E6/E7 cell lines for 48 hours with doxycycline-induced KRAS expression. The image is representative of three independent experiments. B, Immunoblot of NIH “RASless” MEFs expressing BRAFV600E and KRASWT/G12D/R. The image is representative of three independent experiments. C, Immunoblot analysis from murine KPC cell lines after inhibition using the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Blots are representative of two independent experiments. D, Immunoblot analysis of human KRASG12D PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of three independent experiments. E, Immunoblots with human KRASG12D PDX VMP PDAC cell lines after inhibition with the KRASG12D-specific inhibitor MRTX1133 at 20 nmol/L for 4 hours. Quantification of pAKTT308 after inhibition is shown underneath the blot. Data are representative of two independent experiments. F, Box-and-whisker plot with quantification of pAKTT308 in murine PDAC from C and human PDAC from D and E. P values were calculated using a Student t test comparing MRTX1133-treated cells with vehicle-treated cells. ***, P < 0.0002; ns, nonsignificant, P > 0.05. Error bars, mean ± SEM. Statistical tests were run using R 4.2.2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Whole-body KrasLSL-G12R expression via Rosa26Cre-ERT2 drives heterogeneous hyperplasia in multiple tissues and increases endocrine pancreatic vacuole formation. A, Schematic of the KRRC. B, KRRC mice and littermate controls between 24 and 28 days received tamoxifen at 1 mg/10 g of body weight for 5 consecutive days via i.p. injections. C, Kaplan–Meier survival curves for KDRC mice: n = 11 (seven males and four females), Rosa26Cre-ER/LSL-EYFP control: n = 6 (three males and three females), KRRC mice: n = 5 (two males and three females), and KRRC controls: n = 2 (one male and one female). D, H&E staining of KRRC mouse tissues from the lung, spleen, liver, small intestine, and pancreas. A small tumor was detected in a single lobe of the lung in one KRRC mouse (black arrow). No major differences were observed in the spleen and liver between KRRC and control mice. Hyperplasia of the small intestine was observed in 2/5 KRRC mice (black arrow). KRRC mice also exhibited increased vacuole presence within exocrine cells of the pancreas (black arrow). Scale bar, 50 μm. E, Lung sections were immunostained for pErk1/2 and Ki-67 and false-colored. Images are representative of two Rosa26Cre-ERT2 control mice (one male and one female) and five KRRC mice (three males and two females). Scale bar, 100 μm. F, Box plot showing the average intensity of pErk1/2 in Rosa26CreERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five fields of view were taken from each lung. P values were calculated using a Student t test comparing control mice with G12R. *, P < 0.05. Error bars, mean ± SEM. G, Box plot showing the average intensity of Ki-67 in the pancreas of Rosa26Cre-ERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five FOV from each mouse (two control and three KRRC). P values were calculated using a Student t test comparing control mice with KRRC. Error bars, mean ± SEM. All statistical tests were run using R 4.2.2. ns, nonsignificant. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Whole-body KrasLSL-G12R expression via Rosa26Cre-ERT2 drives heterogeneous hyperplasia in multiple tissues and increases endocrine pancreatic vacuole formation. A, Schematic of the KRRC. B, KRRC mice and littermate controls between 24 and 28 days received tamoxifen at 1 mg/10 g of body weight for 5 consecutive days via i.p. injections. C, Kaplan–Meier survival curves for KDRC mice: n = 11 (seven males and four females), Rosa26Cre-ER/LSL-EYFP control: n = 6 (three males and three females), KRRC mice: n = 5 (two males and three females), and KRRC controls: n = 2 (one male and one female). D, H&E staining of KRRC mouse tissues from the lung, spleen, liver, small intestine, and pancreas. A small tumor was detected in a single lobe of the lung in one KRRC mouse (black arrow). No major differences were observed in the spleen and liver between KRRC and control mice. Hyperplasia of the small intestine was observed in 2/5 KRRC mice (black arrow). KRRC mice also exhibited increased vacuole presence within exocrine cells of the pancreas (black arrow). Scale bar, 50 μm. E, Lung sections were immunostained for pErk1/2 and Ki-67 and false-colored. Images are representative of two Rosa26Cre-ERT2 control mice (one male and one female) and five KRRC mice (three males and two females). Scale bar, 100 μm. F, Box plot showing the average intensity of pErk1/2 in Rosa26CreERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five fields of view were taken from each lung. P values were calculated using a Student t test comparing control mice with G12R. *, P < 0.05. Error bars, mean ± SEM. G, Box plot showing the average intensity of Ki-67 in the pancreas of Rosa26Cre-ERT2/+ and KrasLSL-G12R/+;Rosa26Cre-ERT2/+ mice. Five FOV from each mouse (two control and three KRRC). P values were calculated using a Student t test comparing control mice with KRRC. Error bars, mean ± SEM. All statistical tests were run using R 4.2.2. ns, nonsignificant. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Pancreas-specific coexpression of KrasLSL-G12D/+;Trp53LSL-R172H/+, but not KrasLSL-G12R/+;Trp53LSL-R172H/+, drives invasive PDAC. A, Schematic of the generation of the KrasLSL-G12R allele. NEO, neomycin resistance cassette and was used as a selectable marker. B, Schematic of the KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM mouse model (KP48). C, Mice and littermate controls (24–28 days old) received tamoxifen (1 mg/10 g body weight) via i.p. injection for five consecutive days. D, Kaplan–Meier survival curves for controls (n = 26), KDP48 (n = 26), and KRP48 (n = 20) mice. E, Gross images of the pancreas (panc) and spleen (spl). Pancreas sections were additionally stained with H&E, immunostained for pErk1/2 and Kras, and stained with Masson’s trichrome. Images are representative of six mice from each cohort (three male; three female). Immunostained markers were false-colored brown for visualization. H&E images were analyzed by a veterinary pathologist. Scale bar, 100 μm. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Pancreas-specific coexpression of KrasLSL-G12D/+;Trp53LSL-R172H/+, but not KrasLSL-G12R/+;Trp53LSL-R172H/+, drives invasive PDAC. A, Schematic of the generation of the KrasLSL-G12R allele. NEO, neomycin resistance cassette and was used as a selectable marker. B, Schematic of the KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM mouse model (KP48). C, Mice and littermate controls (24–28 days old) received tamoxifen (1 mg/10 g body weight) via i.p. injection for five consecutive days. D, Kaplan–Meier survival curves for controls (n = 26), KDP48 (n = 26), and KRP48 (n = 20) mice. E, Gross images of the pancreas (panc) and spleen (spl). Pancreas sections were additionally stained with H&E, immunostained for pErk1/2 and Kras, and stained with Masson’s trichrome. Images are representative of six mice from each cohort (three male; three female). Immunostained markers were false-colored brown for visualization. H&E images were analyzed by a veterinary pathologist. Scale bar, 100 μm. Created in BioRender. Burge, R. (2025) https://BioRender.com/jv6j4ns.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S7 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KRASG12R-mutant cell lines have reduced migration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S7 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KRASG12R-mutant cell lines have reduced migration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
Extended data related to Figure 5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
Extended data related to Figure 5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KrasLSL-G12D/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM promotes PDAC and liver metastases whereas KrasLSL-G12R/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM drives inflammation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
KrasLSL-G12D/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM promotes PDAC and liver metastases whereas KrasLSL-G12R/+;Trp53LSL-R172H/+;p48LSL-Cre-ERTM drives inflammation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Engineering a KrasLSL-G12R/+ murine model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment
Engineering a KrasLSL-G12R/+ murine model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
Extended data related to Figure 1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
Extended data related to Figure 1.